Mycosis Fungoides Treatment Market Outlook 2024 : Expected Market Growth Rate, Major Driver And Segments | Pfizer Inc., Merck & Co. Inc., Bristol Myers Squibb, Abbott Laboratories

"The new report published by The Business Research Company, titled Mycosis Fungoides Treatment Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the mycosis fungoides treatment market size has grown strongly in recent years. It will grow from $0.91 billion in 2023 to $0.97 billion in 2024 at a compound annual growth rate (CAGR) of 6.8%. The mycosis fungoides treatment market size is expected to see strong growth in the next few years. It will grow to $1.26 billion in 2028 at a compound annual growth rate (CAGR) of 6.9%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=15613&type=smp

Increasing Lymphoma Cancer Incidence Fuels Growth Of The Mycosis Fungoides Treatment Market
The rise in lymphoma cancer incidence is expected to propel the growth of the mycosis fungoides treatment market going forward. Lymphoma refers to a cancer of the lymphatic system, which includes the lymph nodes, spleen, thymus gland, and bone marrow. Lymphoma cancer incidence is on the rise due to a combination of various factors, including environmental exposures, increasing viral infections, an aging population, and several lifestyle factors. Mycosis fungoides treatments, such as topical corticosteroids, phototherapy, and systemic therapies, are used in managing cutaneous T-cell lymphomas. These therapies aim to control skin lesions, reduce symptoms, and manage disease progression in lymphoma patients. For instance, in January 2024, according to the American Cancer Society, a US-based non-profit organization, non-Hodgkin lymphoma (NHL) was one of the most common cancers in the United States, accounting for about 4% of all cancers. It was estimated that approximately 80,620 people (44,590 males and 36,030 females) would be diagnosed with NHL, and about 20,140 people (11,780 males and 8,360 females) would die from this cancer in 2024. Therefore, the rise in lymphoma cancer incidence is driving the growth of the mycosis fungoides treatment market.

Advanced Therapies In Mycosis Fungoides Treatment
Major companies operating in the mycosis fungoides treatment market are developing advanced therapies, such as CAR T cell therapy, to enhance the efficacy and specificity of treatments. CAR T cell therapy, or chimeric antigen receptor T cell therapy, is a type of immunotherapy that involves genetically engineering a patient's own T cells to better recognize and attack cancer cells, including those associated with mycosis fungoides. For instance, in September 2022, CRISPR Therapeutics AG, a Switzerland-based biotechnology company, announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX130, the company's wholly-owned allogeneic CAR T cell therapy targeting CD70, for treating Mycosis Fungoides and Sézary Syndrome (MF or SS). This designation is a significant milestone for the CTX130 program, recognizing the transformative potential of this cell therapy in patients with T-cell lymphomas based on promising clinical data. The RMAT designation is part of a dedicated program established under the 21st Century Cures Act to expedite drug development and review processes for genetic therapies intended to treat serious or life-threatening diseases.

The mycosis fungoides treatment market covered in this report is segmented -

1) By Drug Type: Topical Steroids, Mechlorethamine
2) By Treatment Type: Photodynamic Therapy, Radiation Therapy, Targeted Therapy, Chemotherapy
3) By End-user: Hospitals, Private Clinics, Specialty Clinics

Buy Now & Get Exclusive Discount on this Report, Checkout link @ https://www.thebusinessresearchcompany.com/Discount?id=15613&type=discount

Major companies operating in the mycosis fungoides treatment market are Pfizer Inc., Merck & Co. Inc., Bristol Myers Squibb, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Tocris Bioscience, Viatris Inc., Astellas Pharma Inc., Daiichi Sankyo Company, Takeda Pharmaceutical Company Limited, Bausch Health, Eisai Co. Ltd., Horizon Therapeutics plc, Varian Medical Systems, Kyowa Kirin Co. Ltd., Seattle Genetics Inc., Azurity Pharmaceuticals Inc., Innate Pharma S.A., Helsinn Therapeutics, Jubilant Cadista Pharmaceuticals Inc., Elorac Inc., Soligenix Inc., Ceptaris Therapeutics Inc.

Contents of the report:
1. Executive Summary
2. Mycosis Fungoides Treatment Market Report Structure
3. Mycosis Fungoides Treatment Market Trends And Strategies
4. Mycosis Fungoides Treatment Market - Macro Economic Scenario
5. Mycosis Fungoides Treatment Market Size And Growth
…..
27. Mycosis Fungoides Treatment Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/mycosis-fungoides-treatment-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ "

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.